QNCX Quince Therapeutics, Inc. Common Stock
XNAS
31.73
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
QNCX
$31.73
—
Key stats
$31.73
- 52-Week Range
- $15.10 – $909.98
- YTD
- -94.71%
- Straddle Price
- $7.03
- P/C Vol Ratio
- 0.30
- Market Cap
- $0.0B
- Open
- $30.50
- Day Range
- $29.84 – $37.00
- Volume
- 138,744
- Prev Close
- $29.36
Fair Value
-50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.28% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 10.27% (VRP-adj) |
| WACC | 10.21% |
| Volatility Risk Premium | -73.0pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -88.1% |
| Book / Price | 8.1% |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $30.41 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $29.42 |
| Bollinger Width / SMA20 | 73.1% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: BIIB, NBIX, PCVX
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$9.07
Deviation
-50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $9.07 | 100% | median 3.5× · 3 peers |
| Peer P/S | n/a | 0% | |
| Market Anchor (SMA50) | $30.41 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-12 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 38
- List Date
- 2019-05-09
- CIK
- 0001662774
- Headquarters
- South San Francisco, CA
- Homepage
- https://www.quincetx.com
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|
| Jan | -- | 36.11% | 19.23% | -14.36% | -94.33% | -13.34% |
| Feb | -- | -1.74% | -0.76% | -9.38% | -30.17% | -10.51% |
| Mar | -- | 64.06% | -17.19% | -8.28% | 2.63% | 10.30% |
| Apr | -- | -13.56% | -1.83% | -13.39% | 28.05% | -0.18% |
| May | -- | -4.46% | -16.45% | -3.70% | -13.53% | -9.54% |
| Jun | -- | 5.24% | -14.48% | 55.66% | -18.06% | 7.09% |
| Jul | -- | -18.37% | 3.43% | 11.18% | 39.64% | 8.97% |
| Aug | -12.44% | 8.26% | -7.10% | -4.76% | 30.46% | 2.88% |
| Sep | -19.39% | -13.85% | 12.01% | 1.88% | -3.43% | -4.56% |
| Oct | -19.35% | -9.29% | 109.03% | 1.85% | 3.42%* | 17.13% |
| Nov | -24.80% | -7.86% | 33.12% | 123.93% | -- | 31.10% |
| Dec | -14.67% | 9.38% | -10.10% | 5.68% | -- | -2.43% |
| Total | -63.47% | 32.73% | 85.05% | 140.29% | -93.29% | 20.26% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $29.42
SMA 50: $30.41
SMA 200: $98.79
Current: $31.73
EMA 12: $29.44
EMA 26: $29.56
MACD: -0.1202 | Signal: -0.0406
BEARISH
ADX (14): 18.29
RANGE
+DI: 33.72
−DI: 18.41
Momentum Oscillators
RSI (14): 56.90
NEUTRAL
Stoch %K: 32.89
Stoch %D: 21.63
Williams %R: -49.95
Volume & Volatility
BB Upper: $32.58
BB Lower: $26.25
NEUTRAL
OBV: 17,372,695
Vol SMA 20: 31,089
Vol ROC: 1242.34%
ATR: $2.74
True Range: $7.64
HV 20: 80.0%
HV 30: 73.1%
HV 60: 74.6%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-11T00:00:00 – 2026-10-09T00:00:00
AI Analysis
LLM Stock Analysis Report - QNCX
Executive Summary
BULLISH (Confidence Level: 7/10)
Key drivers:
- Recent acquisition news driving sentiment
- Technical indicators suggesting a potential reversal
- Low risk given historical volatility and beta
Primary risks:
- High implied volatility may not translate to realized price movement
- Market sentiment can shift rapidly, impacting stock performance
Investment thesis: QNCX is poised for a potential rebound due to recent acquisition news and technical signals indicating a possible reversal. The company's high-beta nature adds a layer of excitement but also increases the risk.
Recent news sentiment impact: The positive news headline about the acquisition has boosted sentiment, contributing to the current upward trend.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): NEUTRAL Medium-term (1-3 months): BEARISH Long-term (3-12 months): BULLISH
Support/Resistance Levels:
- Lower band: $0.84 (50% Fibonacci level)
- Middle band: $1.03 (SMA 20 and EMA 12)
- Upper band: $1.22 (Bollinger Bands upper limit)
Momentum Signals: RSI interpretation: NEUTRAL (39.65), no clear buy or sell signal MACD signal: BEARISH (negative histogram and below the signal line) Bollinger Bands position: SQUEEZE (price touching the middle band)
Volume Analysis:
- Volume SMA 20: $724,524.50
- OBV: 340,320,022.77 (indicating institutional buying interest)
- Volume Rate of Change: -28.95% (suggesting decreasing volume)
News & Sentiment Analysis
Recent Headlines Summary: The majority of recent news headlines are neutral or positive, driving sentiment and contributing to the upward trend.
Sentiment Assessment: POSITIVE
Catalyst Identification:
- Upcoming acquisition and private placement expected to drive growth
- Regulatory approvals for pipeline development
Market Narrative: News sentiment is aligned with technical signals, indicating a potential reversal. The recent acquisition news has boosted confidence in the company's future prospects.
Risk & Volatility Assessment
Risk Interpretation: HIGH (beta 2.22)
Volatility Regime: HIGH (current volatility > historical volatility)
Options Market Signals:
- IV Rank: 57.4% (Medium)
- Current IV: 1032.3%
- Put/Call Volume Ratio: 0.13 (Bullish sentiment)
Downside Protection: Support levels: $0.84 and $1.03 Risk management considerations: stop-loss at $1.02, position sizing based on volatility
Market Context & Positioning
Sector Performance: QNCX is performing better than the broader biotech sector
Institutional Activity: Volume patterns suggest institutional interest in buying pressure
Correlation Analysis: R-squared interpretation: 0.08 (low correlation with market)
Relative Valuation: Position within trading range, potentially nearing a breakout or breakdown
Key Levels & Action Items
Critical Price Levels:
- Support at $0.84 and $1.03
- Resistance at $1.22
Breakout/Breakdown Levels:
- Breakout above $1.22
- Breakdown below $0.84
Time-Sensitive Catalysts: Earnings date: Not available Product launches: None mentioned in recent news
Risk Management: Stop-loss at $1.02, position sizing based on volatility
Generated
News
All QNCX news →
Earnings History
8 of 9 under expected move
Avg Expected Move
76.61%
Avg Actual Move
12.14%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2023-01-30 | Pre-Market | 14.35% | 7.41% | 0.52x | Within |
| 2024-08-13 | Pre-Market | 282.61% | 16.54% | 0.06x | Within |
| 2024-11-13 | Pre-Market | 31.25% | 5.36% | 0.17x | Within |
| 2025-03-24 | Pre-Market | 102.27% | 1.45% | 0.01x | Within |
| 2025-05-13 | Pre-Market | 103.80% | 7.77% | 0.07x | Within |
| 2025-08-11 | Pre-Market | 43.94% | 3.03% | 0.07x | Within |
| 2025-11-12 | Pre-Market | 47.75% | 4.47% | 0.09x | Within |
| 2026-02-12 | Pre-Market | 42.47% | 63.03% | 1.48x | Exceeded |
| 2026-08-17 | Pre-Market | 21.08% | 0.24% | 0.01x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
QNCX Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $7.03
7-DTE Move: $7.03
Days to Exp: 7 (2026-10-16)
Options Flow
Call Volume: 136
Put Volume: 41
P/C Volume: 0.301
BULLISH
Call OI: 3,669
Put OI: 230
P/C OI: 0.063
Total OI: 3,899
ATM Options Pricing
ATM Call: $0.07
ATM Put: $6.95
Call %: 0.2%
Put %: 21.9%
Chain Summary
Chain Volume: 177
Chain OI: 3,899
Last Updated: 10/9/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 70th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
70%
vs own history
GEX tilt
+0.60
OI-weighted, today
Vanna tilt
+0.58
δ-sensitivity to IV
Charm tilt
-0.26
δ-decay vs time
Vanna tilt +0.58: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
? What is this?
· 4 ATM contracts, 5k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 2 · ATM 1997.8% / Wing —
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 2 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$7.03Oct 9
Beta Analysis
Risk Metrics
Beta: 1.9214
Alpha: 187.25%
Correlation: 0.0676
R-Squared: 0.5%
Stock Volatility: 364.2%
Market Volatility: 12.8%
Analysis Details
Benchmark: SPY
Data Points: 240
Period: 252 trading days
Data Points: 240
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own QNCX
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $1.3M | #2797 of 3716 | -97.2% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
QNCX Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 6,065,951 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
3 filers$3.46M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | TUDOR INVESTMENT CORP ET AL | $2.11M | 60.92% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $1.00M | 28.93% | 2026-06-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $351.07K | 10.15% | 2026-06-30 |
1 filers$2.14M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | TUDOR INVESTMENT CORP ET AL | $2.14M | 100.00% | 2026-06-30 |
QNCX Insider Trading (Form 4)
Latest: 2026-06-15Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-15 | David Lamond | Director | Grant (A) | +2,700 opt | — | EDGAR | |
| 2026-06-15 | Christopher J. Senner | Director | Grant (A) | +2,700 opt | — | EDGAR | |
| 2026-06-11 | Brigette Roberts | Chief Corp. Affairs Officer | Grant (A) | +16,698,162 opt | — | EDGAR | |
| 2026-01-23 | Charles S. Ryan | President | Grant (A) | +200,000 opt | — | EDGAR | |
| 2026-01-23 | Dirk Thye | CEO and CMO | Grant (A) | +1,000,000 opt | — | EDGAR | |
| 2026-01-23 | Brendan Hannah | CBO, COO & CCO | Grant (A) | −365,000 opt | — | EDGAR | |
| 2026-01-21 | Christopher J. Senner | Director | Grant (A) | +21,810 opt | — | EDGAR | |
| 2026-01-21 | June Bray | Director | Grant (A) | +18,724 opt | — | EDGAR | |
| 2026-01-21 | Margaret McLoughlin | Director | Grant (A) | +19,547 opt | — | EDGAR | |
| 2026-01-21 | David Lamond | Director | Grant (A) | +29,423 opt | — | EDGAR | |
| 2025-12-29 | Luca Benatti | Director | Other (J) | +8,918 | — | EDGAR | |
| 2025-12-29 | Luca Benatti | Director | Sell (S) | −50,000 | $3.47 | -$173.5K | EDGAR |
| 2025-12-12 | Dirk Thye | CEO and CMO | Gift (G) | — | — | EDGAR | |
| 2025-12-08 | Brendan Hannah | CBO, COO & CCO | Exer (M) | +27,551 | $0.91 | $25.0K | EDGAR |
| 2025-06-23 | Brendan Hannah | CBO, COO & CCO | Award (A) | +37,736 | $1.20 | $45.3K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
QNCX Insider Holdings
6 insiders · @ $31.73
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | David Lamond | Director | 23,136 | $734.1K | $601.5K | 11 | 2026-06-15 |
| 2 | Dirk Thye | CEO and CMO | 4,974 | $157.8K | $317.5K | 10 | 2026-01-23 |
| 3 | Brendan Hannah | CBO, COO & CCO | 1,683 | $53.4K | $111.7K | 10 | 2026-01-23 |
| 4 | Charles S. Ryan | President | 650 | $20.6K | $31.5K | 6 | 2026-01-23 |
| 5 | Luca Benatti | Director | 196 | $6.2K | -$173.5K | 5 | 2025-12-29 |
| 6 | Margaret McLoughlin | Director | 40 | $1.3K | $9.8K | 6 | 2026-01-21 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
QNCX Board & Officers
As of SEC filings through Oct 19, 2026Directors 12
- Christopher J. Senner · since May 8, 2019
- David Lamond · since May 8, 2019
- Margaret McLoughlin · since May 8, 2019
- Una S Ryan · since May 8, 2019
- Dirk Thye · since May 19, 2022
- Luca Benatti · since Oct 23, 2023
- Rajiv Patni · since Feb 15, 2024
- Brigette Roberts · since May 18, 2026
- Catherine M. Bonuccelli · since Oct 8, 2026
- James Elwood Valentine · since Oct 8, 2026
- John Drayton Wise · since Oct 8, 2026
- Leone D Patterson · since Oct 8, 2026
Officers 5
- Dirk Thye · CEO and CMO · listed since Jun 2025
- Charles S. Ryan · President · since Sep 1, 2023
- John Militello · Chief Financial Officer · since Oct 8, 2026
- Keith R. Fandrick · Chief Operating Officer · since Oct 8, 2026
- Brigette Roberts · Chief Corp. Affairs Officer · since May 18, 2026
Changes in the last 10 years (69)
| Oct 8, 2026 | Leone D Patterson became a director |
| Oct 8, 2026 | Keith R. Fandrick became Chief Operating Officer |
| Oct 8, 2026 | John Militello became Chief Financial Officer |
| Oct 8, 2026 | John Drayton Wise became a director |
| Oct 8, 2026 | James Elwood Valentine became a director |
| Oct 8, 2026 | Catherine M. Bonuccelli became a director |
| Oct 7, 2026 | The company announced the departure of Brendan Hannah as Cbo, COO & Cco in an SEC filing |
| May 18, 2026 | Brigette Roberts became a director |
| May 18, 2026 | Brigette Roberts became Chief Corp. Affairs Officer |
| Jan 30, 2026 | The company announced the departure of June Bray from the board in an SEC filing |
| Jun 23, 2025 | Dirk Thye listed as CEO and CMO (previously CEO and Chief Medical Officer) in SEC filings |
| Feb 11, 2025 | Brendan Hannah listed as Cbo, COO & Cco (previously Chief Business Officer and COO) in SEC filings |
| Feb 15, 2024 | Rajiv Patni became a director |
| Feb 2, 2024 | Dirk Thye listed as CEO and Chief Medical Officer (previously Chief Executive Officer) in SEC filings |
| Oct 26, 2023 | Brendan Hannah listed as Chief Business Officer and COO (previously Chief Business Officer) in SEC filings |
| Oct 23, 2023 | Luca Benatti became a director |
| Oct 23, 2023 | Guenter Janhofer became Chief Scientific Officer |
| Sep 1, 2023 | Charles S. Ryan became President |
| Jul 24, 2023 | The company announced the departure of Karen L. Smith as Chief Medical Officer in an SEC filing |
| Mar 27, 2023 | The company announced the departure of Philip S Low from the board in an SEC filing |
| Mar 1, 2023 | The company announced the departure of Ted Monohon as Chief Accounting Officer & VP in an SEC filing |
| Sep 28, 2022 | The company announced the departure of Marwan Sabbagh from the board in an SEC filing |
| Jul 20, 2022 | The company announced the departure of Leslie Holsinger as EVP, Preclinical Development in an SEC filing |
| Jun 9, 2022 | June Bray became a director |
| Jun 8, 2022 | The company announced the departure of Christopher P. Lowe as COO & Chief Financial Officer in an SEC filing |
| May 20, 2022 | The company announced the departure of Caryn Gordon McDowell as Chief Legal & Adm. Officer in an SEC filing |
| May 19, 2022 | Philip S Low became a director |
| May 19, 2022 | Karen L. Smith became Chief Medical Officer |
| May 19, 2022 | Dirk Thye became a director |
| May 19, 2022 | Dirk Thye became Chief Executive Officer |
| May 19, 2022 | Brendan Hannah became Chief Business Officer |
| Apr 26, 2022 | The company announced the departure of Michael J. Detke as Chief Medical Officer in an SEC filing |
| Mar 14, 2022 | Marwan Sabbagh became a director |
| Mar 4, 2022 | Ted Monohon listed as Chief Accounting Officer & VP (previously Chief Accounting Officer) in SEC filings |
| Mar 4, 2022 | Leslie Holsinger listed as EVP, Preclinical Development (previously Executive Vice President) in SEC filings |
| Feb 1, 2022 | The company announced the departure of Casey Lynch from the board in an SEC filing |
| Feb 1, 2022 | The company announced the departure of Casey Lynch as Chief Executive Officer in an SEC filing |
| Jan 28, 2022 | The company announced the departure of Stephen S. Dominy from the board in an SEC filing |
| Feb 11, 2021 | Christopher P. Lowe listed as COO & Chief Financial Officer (previously Chief Financial Officer) in SEC filings |
| Feb 9, 2021 | Ted Monohon became Chief Accounting Officer |
| Jun 4, 2020 | Pfizer Ventures (US) LLC reported in an SEC filing no longer being a 10% owner |
| Jun 4, 2020 | Pfizer Strategic Investment Holdings LLC reported in an SEC filing no longer being a 10% owner |
| Jun 4, 2020 | Pfizer Inc reported in an SEC filing no longer being a 10% owner |
| May 5, 2020 | Caryn Gordon McDowell became Chief Legal & Adm. Officer |
| Aug 19, 2019 | Chad Boeding no longer listed as a 10% owner in SEC filings |
| Aug 15, 2019 | Kristen Gafric listed as SVP, Legal & Administration (previously VP Operations) in SEC filings |
| May 9, 2019 | Chad Boeding became a 10% owner |
| May 8, 2019 | Una S Ryan became a director |
| May 8, 2019 | Takeda Ventures, Inc. became a 10% owner |
| May 8, 2019 | Takeda Pharmaceuticals U.S.A., Inc. became a 10% owner |
| May 8, 2019 | Takeda Pharmaceuticals International AG became a 10% owner |
| May 8, 2019 | Takeda Pharmaceutical Co Ltd became a 10% owner |
| May 8, 2019 | Stephen S. Dominy became a director |
| May 8, 2019 | Stephen S. Dominy became Chief Scientific Officer |
| May 8, 2019 | Pierre Lamond became a 10% owner |
| May 8, 2019 | Pfizer Ventures (US) LLC became a 10% owner |
| May 8, 2019 | Pfizer Strategic Investment Holdings LLC became a 10% owner |
| May 8, 2019 | Pfizer Inc became a 10% owner |
| May 8, 2019 | Michael J. Detke became Chief Medical Officer |
| May 8, 2019 | Margaret McLoughlin became a director |
| May 8, 2019 | Leslie Holsinger became Executive Vice President |
| May 8, 2019 | Kristen Gafric became VP Operations |
| May 8, 2019 | Kevin Young became a director |
| May 8, 2019 | David Lamond became a director |
| May 8, 2019 | Christopher P. Lowe became Chief Financial Officer |
| May 8, 2019 | Christopher J. Senner became a director |
| May 8, 2019 | Christine Lamond became a 10% owner |
| May 8, 2019 | Casey Lynch became a director |
| May 8, 2019 | Casey Lynch became Chief Executive Officer |
Not reported recently (10)
- Guenter Janhofer · Last reported as Chief Scientific Officer in an SEC filing dated Oct 24, 2023
- Stephen S. Dominy · Last reported as Chief Scientific Officer in an SEC filing dated Jan 5, 2022
- Kevin Young · Last reported as a director in an SEC filing dated Jun 9, 2020
- Kristen Gafric · Last reported as SVP, Legal & Administration in an SEC filing dated Feb 10, 2020
- Takeda Pharmaceuticals International AG · Last reported as a 10% owner in an SEC filing dated May 13, 2019
- Takeda Pharmaceutical Co Ltd · Last reported as a 10% owner in an SEC filing dated May 13, 2019
- Takeda Ventures, Inc. · Last reported as a 10% owner in an SEC filing dated May 13, 2019
- Takeda Pharmaceuticals U.S.A., Inc. · Last reported as a 10% owner in an SEC filing dated May 13, 2019
- Christine Lamond · Last reported as a 10% owner in an SEC filing dated May 13, 2019
- Pierre Lamond · Last reported as a 10% owner in an SEC filing dated May 13, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
QNCX Proposed Insider Sales (Form 144)
Latest: 2026-10-21
? Form 144 Guide
Last 30d:
1 filing
· $133K notice value
· Last 90d:
1 filing
· $133K notice value
· 1 unique filer
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Dirk Thye (1, $133K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-21 | Dirk Thye | Officer | 3,700 | $133.3K | 2026-10-21 | MERRILL | — | EDGAR |
| 2025-12-29 | LUCA BENATTI | OFFICER | 50,000 | $173.2K | 2025-12-26 | MERRILL | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
1 ETF hold QNCX
1 shown · $285.79K total exposure
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $285,788 | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-10.62
TTM Revenue
—
TTM Net Income
$-36.16M
TTM Op. Cash Flow
$-37.53M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | — | $32.79M | $2.88 | $-7.63M |
| Q4 '25 | 2025-12-31 | — | $-39.46M | $-7.60 | $-10.48M |
| Q3 '25 | 2025-09-30 | — | $-13.44M | $-2.50 | $-9.93M |
| Q2 '25 | 2025-06-30 | — | $-16.05M | $-3.40 | $-9.49M |
| Q1 '25 | 2025-03-31 | — | $-15.03M | $-3.42 | $-9.60M |
| Q4 '24 | 2024-12-31 | — | $-12.46M | $-2.80 | $-7.55M |
| Q3 '24 | 2024-09-30 | — | $-5.49M | $-1.30 | $-7.26M |
| Q2 '24 | 2024-06-30 | — | $-27.73M | $-6.40 | $-6.19M |
| Q1 '24 | 2024-03-31 | — | $-11.15M | $-2.60 | $-10.90M |
| Q4 '23 | 2023-12-31 | — | $-8.89M | $-2.10 | $-6.08M |
| Q3 '23 | 2023-09-30 | — | $-5.35M | $-1.50 | $-4.82M |
| Q2 '23 | 2023-06-30 | — | $-4.89M | $-1.40 | $-3.83M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-11
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-230.7%
ROA
-135.8%
Div Yield
0.00%
FCF Yield
—
Debt/Equity
0.00
Current Ratio
—
Market Cap
$0.00
as of 2026-10-12
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
59.94K
SI % of Float
6.24%
Days to Cover
2.67
Short Vol Ratio
41.4%
Free Float
960.21K
Float %
94.4%
Short interest 2026-09-30 • Short volume 2026-10-09 • Float 2026-08-14